

**Online supplementary table 1** Events in the open-label phase due to the COVID-19 pandemic: protocol deviations, discontinuation of study drug and withdrawal from study

<b>Patients with events, n (%)</b>	<b>Tofacitinib 5 mg BID (N=133)</b>	<b>Placebo→ tofacitinib 5 mg BID (N=136)</b>
<b>Protocol deviations</b>	21 (15.8)	22 (16.2)
Did not remain on stable dose of permitted concomitant medication as specified per protocol	0	2 (1.5)
Revised/updated ICD not signed at the first patient visit after the revised/approved ICD was available at site	0	1 (0.7)
Dosing/administration error: patient temporarily stopped study drug administration for a longer duration than allowed after Week 16 visit	0	2 (1.5)
Lab performed out of visit window	2 (1.5)	0
Lab samples after Week 16 visit were not collected for a study visit	12 (9.0)	14 (10.3)
Patient was a woman of childbearing potential, and pregnancy testing or FSH testing was not performed, or negative test result was not documented prior to dosing	1 (0.8)	0
ECGs not performed at protocol-required time points or out of acceptable time window or not submitted to central vendor	7 (5.3)	9 (6.6)
Efficacy assessments/procedures not performed at appropriate visits	11 (8.3)	14 (10.3)
Patient-reported outcome questionnaires not performed at appropriate visits	0	1 (0.7)
Procedure/test not performed as specified in the protocol	15 (11.3)	16 (11.8)
Missing or incomplete visits or visits occurring outside of allowable visit windows	14 (10.5)	13 (9.6)
<b>Discontinued study drug</b>	0	3 (2.2)
<b>Withdrawal from study by patient</b>	0	2 (1.5)

Data are from the Week 48 final analysis.

All patients had completed the double-blind phase in December 2019. As such, there were no events due to COVID-19 in the double-blind phase. Throughout the study (double-blind and open-label phases), there were no cases of COVID-19.

BID, twice daily; COVID-19, coronavirus disease 2019; ECG, electrocardiogram; FSH, follicle-stimulating hormone; ICD, informed consent document; N, number of patients in safety analysis set; n, number of patients with event.